Tumor-penetrating iRGD peptide inhibits metastasis

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 120-128

  Sugahara, Kazuki N ^a,b   Braun, Gary B ^a,c   De Mendoza, Tatiana Hurtado ^a   Kotamraju, Venkata Ramana ^a   French, Randall P ^d   Lowy, Andrew M ^d   Teesalu, Tambet ^a,e   Ruoslahti, Erkki ^a,c  

^a BURNHAM INSTITUTE   (United States)

^b Department of Surgery Columbia University College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Faculty of Medicine   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTEGRIN; IRGD PEPTIDE; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; CELL PENETRATING PEPTIDE; METAL NANOPARTICLE; NEUROPILIN 1; OLIGOPEPTIDE; SILVER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REPEATED DRUG DOSE; TREATMENT DURATION; ANIMAL; ANTIBODY SPECIFICITY; CELL MOTION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; MALE; METAL NANOPARTICLES; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEUROPILIN-1; OLIGOPEPTIDES; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; SILVER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921345680     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0366     Document Type: Article

References (42)

1. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002;62:5381-5.
2. Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-3.
3. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013;73:2412-7.
4. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34.
5. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancer-secreted miR105 destroys endothelial barriers to promote metastasis. Cancer Cell 2014;25:501-15.
6. Prud'homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012;3:921-39.
7. Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides. Front Oncol 2013;3:216.
8. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end Rule: Peptides with C-terminal arginine cause neuropilin-1 dependent internalization, vascular leakage and tissue penetration. Proc Natl Acad Sci U S A 2009;106:16157-62.
9. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-20.
10. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
11. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.
12. Feron O. Tumor-penetrating peptides: a shift from magic bullets to magic guns. Sci Transl Med 2010;2:34ps26.
13. Yang M, Jiang P, Sun FX, Hasegawa S, Baranov E, Chishima T, et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 1999;59:781-6.
14. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, et al. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res 2010;16:3684-95.
15. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 2004;279:4541-50.
16. Braun GB, Friman T, Pang HB, Pallaoro A, de Mendoza TH, Willmore AMA, et al. Etchable plasmonic nanoparticle probes for cell biology. Nat Mater 2014;13:904-11.
17. Ruoslahti E, Hayman EG, Pierschbacher MD, Engvall E. Fibronectin: purification, immunochemical properties, and biological activities. Methods Enzymol 1982;82:803-31.
18. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-87.
19. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993;268:20205-10.
20. Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, et al. De novo design of a tumor-penetrating peptide. Cancer Res 2013;73:804-12.
21. Saiki I, Murata J, Iida J, Sakurai T, Nishi N, Matsuno K, et al. Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. Br J Cancer 1989;60:722-8.
22. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 2009;105:9343-8.
23. Ye Y, Xu B, Nikiforovich GV, Bloch S, Achilefu S. Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging. Bioorg Med Chem Lett 2011;21:2116-20.
24. Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Alemán C, et al. Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor. J Struct Biol 2013;182:78-86.
25. Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993;75:217-27.
26. He Z, Tessier-Lavigne M. Neuropilin is a receptor of the axonal chemorepellent Semaphorin III. Cell 1997;90:739-51.
27. Parker MW, Linkugel AD, Vander Kooi AW. Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1. J Mol Biol 2013;425:4405-14.
28. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008;8:632-45.
29. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells tomove. Nat Rev Mol Cell Biol 2005;6:789-800.
30. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004;114:1260-71.
31. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003;424:391-7.
32. Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, et al. Enhancement of tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 2014;13:651-61.
33. Woo S, Gomez TM. Rac1 and RhoA promote neurite outgrowth through formation and stabilization of growth cone point contacts. J Neurosci 2006;26:1418-28.
34. Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 2009;10:21-33.
35. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995;64:403-34.
36. Valdembri D, Caswell PT, Anderson KI, Schwarz JP, König I, Astanina E, et al. Neuropilin-1/GIPC1 signaling regulates a5b1 integrin traffic and function in endothelial cells. PLoS Biol 2009;7:e1000025.
37. Bagri A, Tessier-Lavigne M, Watts RJ. Neuropilins in tumor biology. Clin Cancer Res 2009;15:1860-4.
38. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
39. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanism. Nat Rev Cancer 2003;3:362-74.
40. Luo Y, Raper JA. Inhibitory factors controlling growth cone motility and guidance. Curr Opin Neurobiol 1994;4:648-54.
41. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012;122:1832-48.
42. Carmeliet P, Jain RK. Principles and mechanisms of vesel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.